Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Riyadh, The Kingdom of Saudi Arabia: Takeda, the global biopharmaceutical company, is pleased to announce a new strategic ...

Lasell University president Eric Turner is hoping that many Lasell students will find success in the real world by spending ...

Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

DelveInsight's“Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted ...

High Blood Pressure has become a major public health concern in recent times. Research into natural remedies for health ...

Azitra, Inc. , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at The Microcap Conference 2025 ...

The Public Theater and Ma-Yi Theater Company will soon present the New York premiere of SUMO, a thrilling new play written by ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its ...